[1]
|
Xu, S.-H., Huang, J.-Z., Chen, M., et al. (2017) Amplification of ACK1 Promotes Gastric Tumorigenesis via ECD-Dependent p53 Ubiquitination Degradation. Oncotarget, 8, 12705-12716. https://doi.org/10.18632/oncotarget.6194
|
[2]
|
Li, Z.N., Powell, C.E., Groendyke, B.J., et al. (2020) Discovery of a Series of Benzopyrimidodiazepinone TNK2 Inhibitors via Scaffold Morphing. Bioorganic & Medicinal Chemistry Letters, 30, Article 127456. https://doi.org/10.1016/j.bmcl.2020.127456
|
[3]
|
Mahajan, K. and Mahajan, N.P. (2010) Shepherding AKT and Androgen Receptor by ACK1 Tyrosine Kinase. Journal of Cellular Physiology, 224, 327-333. https://doi.org/10.1002/jcp.22162
|
[4]
|
Prieto-Echagüe, V., Gucwa, A., Brown, D.A., et al. (2010) Regulation of ACK1 Localization and Activity by the Amino-Terminal SAM Domain. BMC Biochemistry, 11, Article No. 42. https://doi.org/10.1186/1471-2091-11-42
|
[5]
|
Prieto-Echagüe, V., Gucwa, A., Craddock, B.P., et al. (2010) Cancer-Associated Mutations Activate the Nonreceptor Tyrosine Kinase ACK1. The Journal of Biological Chemistry, 285, 10605-10615. https://doi.org/10.1074/jbc.M109.060459
|
[6]
|
Lin, Q., Wang, J., Childress, C., et al. (2012) The Activation Mechanism of ACK1 (Activated Cdc42-Associated Tyrosine Kinase 1). The Biochemical Journal, 445, 255-264. https://doi.org/10.1042/BJ20111575
|
[7]
|
Fox, M., Mott, H.R. and Owen, D. (2020) Class IA PI3K Regulatory Subunits: p110-Independent Roles and Structures. Biochemical Society Transactions, 48, 1397-1417. https://doi.org/10.1042/BST20190845
|
[8]
|
Fox, M., Crafter, C. and Owen, D. (2019) The Non-Receptor Tyrosine Kinase ACK: Regulatory Mechanisms, Signalling Pathways and Opportunities for attACKing Cancer. Biochemical Society Transactions, 47, 1715-1731. https://doi.org/10.1042/BST20190176
|
[9]
|
Geering, B., Cutillas, P.R., Nock, G., et al. (2007) Class IA Phosphoinositide 3-Kinases Are Obligate p85-p110 Heterodimers. Proceedings of the National Academy of Sciences of the United States of America, 104, 7809-7814. https://doi.org/10.1073/pnas.0700373104
|
[10]
|
Fu, Z., Aronoff-Spencer, E., Backer, J.M., et al. (2003) The Structure of the Inter-SH2 Domain of Class IA Phosphoinositide 3-Kinase Determined by Site-Directed Spin Labeling EPR and Homology Modeling. Proceedings of the National Academy of Sciences of the United States of America, 100, 3275-3280. https://doi.org/10.1073/pnas.0535975100
|
[11]
|
Wang, G.Q., Zhang, M.Z., Jang, H.B., et al. (2018) Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit. Biochemistry, 57, 1917-1928. https://doi.org/10.1021/acs.biochem.7b01130
|
[12]
|
Nur-E-Kamal, A., Zhang, A., Keenan, S.M., et al. (2005) Requirement of Activated Cdc42-Associated Kinase for Survival of v-Ras-Transformed Mammalian Cells. Molecular Cancer Research, 3, 297-305. https://doi.org/10.1158/1541-7786.MCR-04-0152
|
[13]
|
Cox, K.J., Shomin, C.D. and Ghosh, I. (2011) Tinkering Outside the Kinase ATP Box: Allosteric (Type IV) and Bivalent (Type V) Inhibitors of Protein Kinases. Future Medicinal Chemistry, 3, 29-43. https://doi.org/10.4155/fmc.10.272
|
[14]
|
Lawrence, H.R., Mahajan, K., Luo, Y., et al. (2015) Development of Novel ACK1/TNK2 Inhibitors Using a Fragment-Based Approach. Journal of Medicinal Chemistry, 58, 2746-2763. https://doi.org/10.1021/jm501929n
|
[15]
|
Mahajan, K. and Mahajan, N.P. (2012) PI3K-Independent AKT Activation in Cancers: A Treasure Trove for Novel Therapeutics. Journal of Cellular Physiology, 227, 3178-3184. https://doi.org/10.1002/jcp.24065
|
[16]
|
Mahajan, K. and Mahajan, N.P. (2013) ACK1 Tyrosine Kinase: Targeted Inhibition to Block Cancer Cell Proliferation. Cancer Letters, 338, 185-192. https://doi.org/10.1016/j.canlet.2013.04.004
|
[17]
|
Zhang, N., Zeng, X., Sun, C., et al. (2019) LncRNA LINC00963 Promotes Tumorigenesis and Radioresistance in Breast Cancer by Sponging miR-324-3p and Inducing ACK1 Expression. Molecular Therapy Nucleic Acids, 18, 871-881. https://doi.org/10.1016/j.omtn.2019.09.033
|
[18]
|
Sawant, M., Wilson, A., Sridaran, D., et al. (2023) Epigenetic Reprogramming of Cell Cycle Genes by ACK1 Promotes Breast Cancer Resistance to CDK4/6 Inhibitor. Oncogene, 42, 2263-2277. https://doi.org/10.1038/s41388-023-02747-x
|
[19]
|
Buchwald, M., Pietschmann, K., Brand, P., et al. (2013) SIAH Ubiquitin Ligases Target the Nonreceptor Tyrosine Kinase ACK1 for Ubiquitinylation and Proteasomal Degradation. Oncogene, 32, 4913-4920. https://doi.org/10.1038/onc.2012.515
|
[20]
|
Karaca, M., Liu, Y., Zhang, Z., et al. (2015) Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. PLOS ONE, 10, e0126270. https://doi.org/10.1371/journal.pone.0126270
|
[21]
|
Mahajan, K., Coppola, D., Challa, S., et al. (2010) ACK1 Mediated AKT/PKB Tyrosine 176 Phosphorylation Regulates Its Activation. PLOS ONE, 5, e9646. https://doi.org/10.1371/journal.pone.0009646
|
[22]
|
Brandao, R., Kwa, M.Q., Yarden, Y., et al. (2021) ACK1 Is Dispensable for Development, Skin Tumor Formation, and Breast Cancer Cell Proliferation. FEBS Open Bio, 11, 1579-1592. https://doi.org/10.1002/2211-5463.13149
|
[23]
|
Mahajan, K., Malla, P., Lawrence, H.R., et al. (2017) ACK1/TNK2 Regulates Histone H4 Tyr88-Phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer. Cancer Cell, 31, 790-803. https://doi.org/10.1016/j.ccell.2017.05.003
|
[24]
|
Mahajan, N.P., Whang, Y.E., Mohler, J.L., et al. (2005) Activated Tyrosine Kinase ACK1 Promotes Prostate Tumorigenesis: Role of ACK1 in Polyubiquitination of Tumor Suppressor Wwox. Cancer Research, 65, 10514-10523. https://doi.org/10.1158/0008-5472.CAN-05-1127
|
[25]
|
Xie, B., Zen, Q., Wang, X., et al. (2015) ACK1 Promotes Hepatocellular Carcinoma Progression via Downregulating WWOX and Activating AKT Signaling. International Journal of Oncology, 46, 2057-2066. https://doi.org/10.3892/ijo.2015.2910
|
[26]
|
Sridaran, D., Chouhan, S., Mahajan, K., et al. (2022) Inhibiting ACK1-Mediated Phosphorylation of C-Terminal Src Kinase Counteracts Prostate Cancer Immune Checkpoint Blockade Resistance. Nature Communications, 13, Article No. 6929. https://doi.org/10.1038/s41467-022-34724-5
|
[27]
|
Mahajan, N.P., Liu, Y., Majumder, S., et al. (2007) Activated Cdc42-Associated Kinase ACK1 Promotes Prostate Cancer Progression via Androgen Receptor Tyrosine Phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 104, 8438-8443. https://doi.org/10.1073/pnas.0700420104
|
[28]
|
De Silva, D., Zhang, Z., Liu, Y., et al. (2019) Interaction between Androgen Receptor and Coregulator SLIRP Is Regulated by ACK1 Tyrosine Kinase and Androgen. Scientific Reports, 9, Article No. 18637. https://doi.org/10.1038/s41598-019-55057-2
|
[29]
|
Chouhan, S., Sawant, M., Weimholt, C., et al. (2023) TNK2/ACK1-Mediated Phosphorylation of ATP5F1A (ATP Synthase F1 Subunit Alpha) Selectively Augments Survival of Prostate Cancer While Engendering Mitochondrial Vulnerability. Autophagy, 19, 1000-1025. https://doi.org/10.1080/15548627.2022.2103961
|
[30]
|
Xu, S.-H., Huang, J.-Z., Xu, M.-L., et al. (2015) ACK1 Promotes Gastric Cancer Epithelial-Mesenchymal Transition and Metastasis through AKT-POU2F1-ECD Signalling. The Journal of Pathology, 236, 175-185. https://doi.org/10.1002/path.4515
|
[31]
|
Chua, B.T., Lim, S.J., Tham, S.C., et al. (2010) Somatic Mutation in the ACK1 Ubiquitin Association Domain Enhances Oncogenic Signaling through EGFR Regulation in Renal Cancer Derived Cells. Molecular Oncology, 4, 323-334. https://doi.org/10.1016/j.molonc.2010.03.001
|
[32]
|
Zhu, J., Liu, Y., Ao, H., et al. (2020) Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-Small Cell Lung Cancer. Frontiers in Oncology, 10, Article 1132. https://doi.org/10.3389/fonc.2020.01132
|
[33]
|
Zhu, J.H., Liu, Y., Zhao, M., et al. (2021) Identification of Downstream Signaling Cascades of ACK1 and Prognostic Classifiers in Non-Small Cell Lung Cancer. Aging, 13, 4482-4502. https://doi.org/10.18632/aging.202408
|
[34]
|
Zhang, A.Q., Zhang, R.X., Yang, Z.M., et al. (2021) TNK2 Promoted Esophageal Cancer Progression via Activating Egfr-Akt Signaling. Journal of Clinical Laboratory Analysis, 35, e23700. https://doi.org/10.1002/jcla.23700
|
[35]
|
Yu, X.J., Liu, J., Qiu, H.W., et al. (2021) Combined Inhibition of ACK1 and AKT Shows Potential toward Targeted Therapy against KRAS-Mutant Non-Small-Cell Lung Cancer. Bosnian Journal of Basic Medical Sciences, 21, 198-207. https://doi.org/10.17305/bjbms.2020.4746
|
[36]
|
Gu, J., Qian, L., Zhang, G., et al. (2020) Inhibition of ACK1 Delays and Overcomes Acquired Resistance of EGFR Mutant NSCLC Cells to the Third Generation EGFR Inhibitor, Osimertinib. Lung Cancer, 150, 26-35. https://doi.org/10.1016/j.lungcan.2020.09.023
|
[37]
|
Mahajan, K., Coppola, D., Chen, Y.A., et al. (2012) ACK1 Tyrosine Kinase Activation Correlates with Pancreatic Cancer Progression. The American Journal of Pathology, 180, 1386-1393. https://doi.org/10.1016/j.ajpath.2011.12.028
|
[38]
|
Kong, D., Li, G., Yang, Z., et al. (2022) Identification of an ACK1/TNK2-Based Prognostic Signature for Colon Cancer to Predict Survival and Inflammatory Landscapes. BMC Cancer, 22, Article No. 84. https://doi.org/10.1186/s12885-021-09165-w
|
[39]
|
李芊. 新型选择性ACK1抑制剂的设计合成及抗肿瘤活性研究[D]: [硕士学位论文]. 广州: 暨南大学, 2022.
|
[40]
|
Wu, X., Zahari, M.S., Renuse, S., et al. (2017) The Non-Receptor Tyrosine Kinase TNK2/ACK1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer. Oncotarget, 8, 2971-2983. https://doi.org/10.18632/oncotarget.13579
|
[41]
|
Mahajan, K., Challa, S., Coppola, D., et al. (2010) Effect of ACK1 Tyrosine Kinase Inhibitor on Ligand-Independent Androgen Receptor Activity. The Prostate, 70, 1274-1285. https://doi.org/10.1002/pros.21163
|
[42]
|
Mahajan, K., Coppola, D., Rawal, B., et al. (2012) ACK1-Mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-Resistant Prostate Cancer. The Journal of Biological Chemistry, 287, 22112-22122. https://doi.org/10.1074/jbc.M112.357384
|
[43]
|
Li, J., Rix, U., Fang, B., et al. (2010) A Chemical and Phosphoproteomic Characterization of Dasatinib Action in Lung Cancer. Nature Chemical Biology, 6, 291-299. https://doi.org/10.1038/nchembio.332
|
[44]
|
Liu, Y., Karaca, M., Zhang, Z., et al. (2010) Dasatinib Inhibits Site-Specific Tyrosine Phosphorylation of Androgen Receptor by ACK1 and Src Kinases. Oncogene, 29, 3208-3216. https://doi.org/10.1038/onc.2010.103
|
[45]
|
Tan, D.S., Haaland, B., Gan, J.M., et al. (2014) Bosutinib Inhibits Migration and Invasion via ACK1 in KRAS Mutant Non-Small Cell Lung Cancer. Molecular Cancer, 13, Article No. 13. https://doi.org/10.1186/1476-4598-13-13
|
[46]
|
Wang, A.X., Shuai, W., Wu, C.Y., et al. (2024) Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFRL858R/T790M/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. Journal of Medicinal Chemistry, 67, 2777-2801. https://doi.org/10.1021/acs.jmedchem.3c01934
|